AnaptysBio, Inc. (ANAB) Stock Score, Valuation & Financial Research
AnaptysBio, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 26/100.
Quick answer for ANAB
AnaptysBio, Inc. currently has a Wall Street Score of 26/100. The stored market price is $53.87. Its financial score is 50/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What AnaptysBio, Inc. does
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various an
ANAB financial snapshot
- Wall Street Score:
- 26/100
- Current price:
- $53.87
- Market capitalization:
- $1.60B
- Revenue:
- $232.4M
- Net income:
- $-26.8M
- Free cash flow:
- $19.6M
- Cash:
- $248.5M
- Total debt:
- $277.4M
- EPS:
- -0.87
- Financial score:
- 50/100
- Valuation score:
- 0/100
- Revenue score:
- 21/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $19.6M, showing positive cash generation.
- The balance sheet shows $248.5M of cash versus $277.4M of total debt, so leverage deserves attention.
- The current research record carries a missing opportunity history warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 50/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ANAB
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.